期刊文献+

泛素特异性蛋白酶11在中枢神经系统疾病中的作用研究进展

Recent advance in role of ubiquitin-specific protease 11 in central nervous system diseases
原文传递
导出
摘要 泛素特异性蛋白酶11(USP11)是泛素特异性蛋白酶(USPs)家族成员之一,通过介导底物的去泛素化过程,抑制靶蛋白的泛素-蛋白酶体降解,进而参与细胞周期进程、DNA损伤修复、细胞死亡、自噬、信号传导、免疫炎症反应及大脑皮层发育等多种病理生理过程的调节。研究表明,USP11在中枢神经系统(CNS)疾病的发生发展进程中具有重要作用。本文围绕USP11的结构、功能及其在CNS疾病中的作用机制研究进展进行综述,以期为靶向USP11治疗相关疾病提供新的思路。 Ubiquitin-specific protease 11(USP11)is a family member of deubiquitylases(DUBs).It mediates substrates de-ubiquitination to inhibit their ubiquitin-proteasome degradation and participates in cell cycle process,DNA damage repair,cell death,autophagy,signal transduction,immune inflammatory response,cerebral cortex development,and other physiological processes.Studies show that USP11 also plays an important role in central nervous system diseases.This article starts with the structure and functions of USP11 to systematically review the mechanism of USP11 in central nervous system diseases and provide new ideas for USP11 as a therapeutic target.
作者 杜欣燕 李中中 郭艳苏 Du Xinyan;Li Zhongzhong;Guo Yansu(Beijing Geriatric Healthcare Center,Xuanwu Hospital,Capital Medical University,Beijing 100053,China;Department of Neurology,Second Hospital of Hebei Medical University,Shijiazhuang 050000,China)
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2023年第12期1272-1276,共5页 Chinese Journal of Neuromedicine
基金 国家自然科学基金(81971200) 北京市自然科学基金(7222082)。
关键词 泛素特异性蛋白酶11 脑肿瘤 脊髓缺血再灌注损伤 脑出血 tau蛋白病 Ubiquitin-specific protease 11 Brain tumor Spinal cord ischemia-reperfusion injury Intracerebral hemorrhage Tauopathy
  • 相关文献

参考文献2

二级参考文献12

  • 1Vollmer TL, Hadjimichael O, Preiningerova J, et al. Disability and treatment patterns of multiple sclerosis patients in United States: A comparison of veterans and nonveterans [J]. J Rehabil Res Dev,2002, 39(2): 163-174.
  • 2Pozzilli C, Romano S, Cannoni S. Epidemiology and current treatment of multiple sclerosis in Europe today [J]. J Rehabil Res Dev, 2002, 39(2): 175-185.
  • 3ZivadinovR, RudickRA, DeMasiR, et al. Effects of Ⅳ methylprednisolone on brain atrophy in relapsing-remitting MS [J].Neurology, 2001, 57(7): 1239-1247.
  • 4Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiplesclerosis-current practice and future directions [ J ]. J Rehabil Res Dev, 2002, 39(2): 273-285.
  • 5Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS:clinical results [J]. Neurology, 2001, 56(11 ): 1496-1504.
  • 6Li DK, Zhao GJ, Paty DW. University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group.Randomized controlled trial ofinterferon-beta-la in secondary progressive MS: MRIresults [J]. Neurology, 2001, 56 (11):1505-1513.
  • 7ColesAJ. Neutralising antibodies to the beta interferons [J]. JNeurol Neurosurg Psychiatry, 2002, 73(2): 110-111.
  • 8Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory [J]. J Neurol Neurosurg Psychiatry, 2002, 73(2): 148-153.
  • 9Coyle P. Results of comparative efficacy trial using two formulations of interferon-beta-la in RRMS [J]. J Neurol Sci, 2001, 187 Suppl 1:436.
  • 10Schwid SR, Covington M, Segal BM, et al. Fatigue in multiple sclerosis: Current understanding and future directions [J]. J Rehabil Res Dev, 2002, 39(2): 211-224.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部